Citizens Business Bank Has $766,000 Stake in Johnson & Johnson (NYSE:JNJ)

Citizens Business Bank boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 52.7% during the fourth quarter, Holdings Channel reports. The fund owned 5,297 shares of the company’s stock after purchasing an additional 1,828 shares during the period. Citizens Business Bank’s holdings in Johnson & Johnson were worth $766,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the business. IFS Advisors LLC grew its stake in Johnson & Johnson by 138.9% in the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after buying an additional 100 shares during the last quarter. WealthTrak Capital Management LLC acquired a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $26,000. Mountain Hill Investment Partners Corp. bought a new position in shares of Johnson & Johnson during the fourth quarter worth approximately $29,000. Bay Harbor Wealth Management LLC bought a new stake in Johnson & Johnson in the 4th quarter valued at $32,000. Finally, Conquis Financial LLC acquired a new position in Johnson & Johnson in the 4th quarter valued at $33,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In other news, EVP Timothy Schmid sold 403 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the transaction, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. The trade was a 25.00 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on JNJ shares. Stifel Nicolaus reduced their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research report on Thursday, January 23rd. Wells Fargo & Company lowered their target price on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a report on Thursday, January 23rd. Argus raised Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. The Goldman Sachs Group raised Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $157.00 to $172.00 in a report on Wednesday, April 9th. Finally, Sanford C. Bernstein restated a “market perform” rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $171.82.

Johnson & Johnson Trading Up 1.8 %

NYSE JNJ opened at $157.23 on Thursday. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The business has a 50 day moving average price of $158.35 and a 200-day moving average price of $154.49. The company has a market cap of $378.31 billion, a price-to-earnings ratio of 23.64, a P/E/G ratio of 2.56 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping analysts’ consensus estimates of $2.59 by $0.18. The firm had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. As a group, equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, May 27th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a yield of 3.31%. Johnson & Johnson’s dividend payout ratio (DPR) is 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.